- Home
- ECPG vs CANF Comparison
ECPG vs CANF Comparison
Compare ECPG & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECPG
- CANF
- Stock Information
- Founded
- ECPG 1998
- CANF 1994
- Country
- ECPG United States
- CANF Israel
- Employees
- ECPG N/A
- CANF N/A
- Industry
- ECPG Finance Companies
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- ECPG Finance
- CANF Health Care
- Exchange
- ECPG Nasdaq
- CANF Nasdaq
- Market Cap
- ECPG 806.1M
- CANF 7.9M
- IPO Year
- ECPG 1999
- CANF N/A
- Fundamental
- Price
- ECPG $40.77
- CANF $1.12
- Analyst Decision
- ECPG Strong Buy
- CANF Strong Buy
- Analyst Count
- ECPG 3
- CANF 2
- Target Price
- ECPG $62.67
- CANF $14.00
- AVG Volume (30 Days)
- ECPG 334.9K
- CANF 444.9K
- Earning Date
- ECPG 05-07-2025
- CANF 05-20-2025
- Dividend Yield
- ECPG N/A
- CANF N/A
- EPS Growth
- ECPG N/A
- CANF N/A
- EPS
- ECPG N/A
- CANF N/A
- Revenue
- ECPG $1,380,750,000.00
- CANF $674,000.00
- Revenue This Year
- ECPG $21.62
- CANF $461.72
- Revenue Next Year
- ECPG $10.12
- CANF N/A
- P/E Ratio
- ECPG N/A
- CANF N/A
- Revenue Growth
- ECPG 11.49
- CANF N/A
- 52 Week Low
- ECPG $26.45
- CANF $1.02
- 52 Week High
- ECPG $51.77
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- ECPG 67.68
- CANF 40.25
- Support Level
- ECPG $32.27
- CANF $1.02
- Resistance Level
- ECPG $36.32
- CANF $1.20
- Average True Range (ATR)
- ECPG 1.53
- CANF 0.06
- MACD
- ECPG 0.71
- CANF 0.01
- Stochastic Oscillator
- ECPG 97.88
- CANF 41.30
About ECPG Encore Capital Group Inc
Encore Capital Group Inc is an international specialty finance company. It provides debt recovery solutions for consumers and property owners across a broad range of financial assets. The company purchases portfolios of defaulted consumer receivables at deep discounts to face value and manages them by working with individuals as the consumers repay their obligations and work toward financial recovery. Encore has only a reportable segment portfolio purchasing and recovery.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).